Cencora, Inc. (NYSE:COR) Receives $256.67 Consensus Target Price from Analysts

Cencora, Inc. (NYSE:COR - Get Free Report) has received an average rating of "Moderate Buy" from the nine analysts that are presently covering the company, Marketbeat Ratings reports. Three analysts have rated the stock with a hold recommendation and six have given a buy recommendation to the company. The average 1-year target price among brokers that have issued ratings on the stock in the last year is $256.67.

A number of equities research analysts recently weighed in on COR shares. Leerink Partners reissued an "outperform" rating and set a $275.00 target price on shares of Cencora in a research report on Thursday, June 27th. StockNews.com cut Cencora from a "strong-buy" rating to a "buy" rating in a research report on Friday, September 20th. JPMorgan Chase & Co. upped their target price on Cencora from $280.00 to $287.00 and gave the company an "overweight" rating in a research note on Wednesday, August 21st. Bank of America reiterated a "neutral" rating and set a $245.00 price target (down previously from $275.00) on shares of Cencora in a research note on Wednesday, September 18th. Finally, Robert W. Baird reduced their price objective on shares of Cencora from $287.00 to $283.00 and set an "outperform" rating for the company in a report on Friday, September 6th.

Insiders Place Their Bets

In other news, EVP Silvana Battaglia sold 1,473 shares of Cencora stock in a transaction that occurred on Tuesday, August 6th. The shares were sold at an average price of $242.69, for a total value of $357,482.37. Following the completion of the transaction, the executive vice president now owns 10,948 shares in the company, valued at approximately $2,656,970.12. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. In other Cencora news, CEO Steven H. Collis sold 10,755 shares of the stock in a transaction dated Tuesday, July 16th. The shares were sold at an average price of $222.12, for a total transaction of $2,388,900.60. Following the sale, the chief executive officer now owns 285,088 shares of the company's stock, valued at $63,323,746.56. This represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP Silvana Battaglia sold 1,473 shares of the business's stock in a transaction dated Tuesday, August 6th. The stock was sold at an average price of $242.69, for a total transaction of $357,482.37. Following the completion of the transaction, the executive vice president now directly owns 10,948 shares of the company's stock, valued at approximately $2,656,970.12. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 4,450,399 shares of company stock valued at $1,070,392,799. 15.80% of the stock is currently owned by insiders.

Institutional Trading of Cencora

Hedge funds and other institutional investors have recently modified their holdings of the stock. Rise Advisors LLC acquired a new position in Cencora during the 1st quarter valued at about $25,000. New Millennium Group LLC bought a new position in Cencora in the second quarter valued at approximately $26,000. TCTC Holdings LLC bought a new position in Cencora in the first quarter valued at approximately $29,000. TFO Wealth Partners LLC acquired a new stake in Cencora during the 1st quarter worth $30,000. Finally, MFA Wealth Advisors LLC bought a new stake in shares of Cencora during the 2nd quarter valued at $30,000. Institutional investors and hedge funds own 97.52% of the company's stock.

Cencora Stock Performance

NYSE COR traded down $1.02 during trading on Friday, hitting $219.94. The company's stock had a trading volume of 1,638,164 shares, compared to its average volume of 1,415,768. Cencora has a 52 week low of $182.62 and a 52 week high of $247.66. The firm has a market cap of $43.87 billion, a P/E ratio of 24.06, a price-to-earnings-growth ratio of 1.58 and a beta of 0.44. The firm has a 50 day moving average price of $234.60 and a 200 day moving average price of $232.07. The company has a quick ratio of 0.55, a current ratio of 0.89 and a debt-to-equity ratio of 3.93.

Cencora (NYSE:COR - Get Free Report) last announced its earnings results on Wednesday, July 31st. The company reported $3.34 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $3.18 by $0.16. Cencora had a net margin of 0.65% and a return on equity of 266.60%. The business had revenue of $74.20 billion for the quarter, compared to analyst estimates of $73.32 billion. During the same quarter in the previous year, the firm posted $2.92 earnings per share. Cencora's revenue was up 10.8% compared to the same quarter last year. Equities research analysts forecast that Cencora will post 13.63 earnings per share for the current fiscal year.

Cencora Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Monday, August 26th. Investors of record on Friday, August 9th were issued a dividend of $0.51 per share. This represents a $2.04 annualized dividend and a yield of 0.93%. The ex-dividend date was Friday, August 9th. Cencora's dividend payout ratio is currently 22.32%.

About Cencora

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.